SG10201901676UA - Pyrazolothiazole compound and medicine comprising same - Google Patents
Pyrazolothiazole compound and medicine comprising sameInfo
- Publication number
- SG10201901676UA SG10201901676UA SG10201901676UA SG10201901676UA SG10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- medicine
- same
- effect
- pyrazolothiazole
- Prior art date
Links
- -1 Pyrazolothiazole compound Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000016366 nasal cavity polyp Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME The invention provides a pyrazolothiazolecompound compound of the formula [IJ, or a pharmaceutically 5 acceptable salt thereof: The compound of the invention has JAKI inhibitory activity, and thus, irr~unosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the 10 treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp. Figure for publication: None
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014177969 | 2014-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201901676UA true SG10201901676UA (en) | 2019-03-28 |
Family
ID=55439874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901676UA SG10201901676UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
| SG11201701447UA SG11201701447UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701447UA SG11201701447UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9937176B2 (en) |
| EP (1) | EP3190116B1 (en) |
| JP (1) | JP6558372B2 (en) |
| KR (1) | KR102294330B1 (en) |
| CN (1) | CN107108653B (en) |
| AU (1) | AU2015312886B2 (en) |
| BR (1) | BR112017003800B1 (en) |
| CA (1) | CA2959721C (en) |
| CL (1) | CL2017000478A1 (en) |
| CO (1) | CO2017002982A2 (en) |
| CY (1) | CY1123320T1 (en) |
| DK (1) | DK3190116T3 (en) |
| ES (1) | ES2827243T3 (en) |
| HR (1) | HRP20201382T1 (en) |
| HU (1) | HUE050565T2 (en) |
| IL (1) | IL250729B (en) |
| LT (1) | LT3190116T (en) |
| MA (1) | MA40605B1 (en) |
| MX (1) | MX377926B (en) |
| MY (1) | MY181814A (en) |
| NZ (1) | NZ729494A (en) |
| PE (1) | PE20170668A1 (en) |
| PH (1) | PH12017500383B1 (en) |
| PL (1) | PL3190116T3 (en) |
| PT (1) | PT3190116T (en) |
| RS (1) | RS60798B1 (en) |
| RU (1) | RU2688660C2 (en) |
| SG (2) | SG10201901676UA (en) |
| SI (1) | SI3190116T1 (en) |
| SM (1) | SMT202000503T1 (en) |
| TW (1) | TWI679205B (en) |
| UA (1) | UA121869C2 (en) |
| WO (1) | WO2016035814A1 (en) |
| ZA (1) | ZA201701492B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
| TWI712604B (en) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | Crystal of compound with JAK inhibitory effect |
| WO2018225247A1 (en) | 2017-06-09 | 2018-12-13 | 三菱電機株式会社 | Passenger conveyor |
| EP4081199A4 (en) * | 2019-12-23 | 2024-01-17 | SRI International | Lipoxygenase inhibitors |
| JP7742516B1 (en) * | 2025-07-31 | 2025-09-19 | 日本新薬株式会社 | Treatment for eosinophilic granulomatosis with polyangiitis |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (en) | 1986-01-09 | 1987-07-16 | Hoechst Ag | DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME |
| PH25866A (en) * | 1986-03-20 | 1991-12-02 | Takeda Chemical Industries Ltd | Sulfonylurea compounds and their herbicides |
| US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
| GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| KR101164541B1 (en) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Selective kinase inhibitors |
| MXPA06012510A (en) | 2004-04-28 | 2006-12-15 | Pfizer | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor. |
| NZ567133A (en) * | 2005-09-30 | 2011-07-29 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| NZ592990A (en) * | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| BRPI0909040B8 (en) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | azetidine and cyclobutane derivatives, their uses, and composition |
| US8431603B2 (en) * | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | 3-phenylpyrazolo[5,1-b]thiazole compounds |
| JO3041B1 (en) | 2008-07-25 | 2016-09-05 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JP5490137B2 (en) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Bicyclic pyrazoles as protein kinase inhibitors |
| TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| ES2461967T3 (en) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Pyrrolo [2,3-d] pyrimidine compounds |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP2011136925A (en) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
| CN102712640A (en) | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
| ES2525581T3 (en) | 2010-07-12 | 2014-12-26 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage-dependent sodium channel inhibitors |
| WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| AU2011302216A1 (en) | 2010-09-14 | 2013-04-04 | Exelixis, Inc. | Phtalazine derivatives as JAK1 inhibitors |
| EP2629777B1 (en) | 2010-10-22 | 2018-12-19 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/en active
- 2015-09-02 PT PT158384669T patent/PT3190116T/en unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/en active Active
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/en active Active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 PL PL15838466T patent/PL3190116T3/en unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/en active
- 2015-09-02 RS RS20201081A patent/RS60798B1/en unknown
- 2015-09-02 UA UAA201702990A patent/UA121869C2/en unknown
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/en unknown
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/en not_active Ceased
- 2015-09-02 SM SM20200503T patent/SMT202000503T1/en unknown
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/en unknown
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 ES ES15838466T patent/ES2827243T3/en active Active
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/en active Active
- 2015-09-02 HR HRP20201382TT patent/HRP20201382T1/en unknown
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/en active
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/en active Active
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 CA CA2959721A patent/CA2959721C/en active Active
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/en unknown
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/en unknown
- 2015-09-02 MA MA40605A patent/MA40605B1/en unknown
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 MX MX2017002488A patent/MX377926B/en unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/en active IP Right Grant
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/en unknown
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/en unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123320T1 (en) | PYRAZOLOTHIAZOLE COMPOUND AND DRUG CONTAINING IT | |
| CL2015002468A1 (en) | Processes and intermediates to make a jak inhibitor | |
| PH12016502581A1 (en) | TrK-INHIBITING COMPOUND | |
| EA201591269A1 (en) | METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | |
| EA201891374A1 (en) | SUBSTITUTED 2-PHENYL-3- (PIPERAZINMETHIL) IMIDAZOPIRIDINES AND THEIR APPLICATION | |
| MX386256B (en) | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR IL-17 INHIBITION AND OTHER USES. | |
| NZ701700A (en) | Bicyclically substituted uracils and the use thereof | |
| IL283469A (en) | Inhalable compositions for use in the treatment of pulmonary diseases | |
| HK1217092A1 (en) | Therapeutic compounds and uses thereof | |
| EP3091959A4 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| CY1123607T1 (en) | A JAK-INHIBITING COMPOUND CRYSTAL | |
| EA201790072A1 (en) | DERIVATIVES 2-ARYL-4-HYDROXY-1,3-TIAZOLE FOR USE AS TRPM8 INHIBITORS IN THE TREATMENT OF NEURALGIA, PAIN, CHRONIC OBSTRUCTIVE LUNG AND ASTHMA | |
| WO2014179214A3 (en) | Human rhinovirus (hrv) anitbodies | |
| EP3384285A4 (en) | TREATMENT OF FIBROTIC DISORDERS | |
| HK40063829A (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine | |
| HK40078514A (en) | Treatment of lower airways disorders | |
| MX370251B (en) | Diphenylox. | |
| MX2019014773A (en) | Ccl2 inhibitors. | |
| GB201802354D0 (en) | Treatment of chronic obstructive pulmonary disease | |
| GB201802353D0 (en) | Treatment of chronic obstructive pulmonary disease | |
| TH1701001056A (en) | Pyrazolothiazole and its medicinal compounds include them. | |
| MX2015016549A (en) | Combination of oxymetazoline and ipratropium in topical nasal application for the cough treatment. | |
| TH171834A (en) | Respiratory disease treatment | |
| TH149184A (en) | New aryl-enriched camphenes, processes for their preparation and their applications | |
| UA93635U (en) | Pharmaceutical composition for treatment of chronic obstructive diseases of lungs |